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Abstract
Many studies are currently investigating the development of safe and effective vaccines to prevent various
infectious diseases. Multiple antigen-presenting peptide vaccine systems have been developed to avoid the
adverse effects associated with conventional vaccines (i.e., live-attenuated, killed or inactivated pathogens), carrier
proteins and cytotoxic adjuvants. Recently, two main approaches have been used to develop multiple antigen-
presenting peptide vaccine systems: (1) the addition of functional components, e.g., T-cell epitopes, cell-penetrating
peptides, and lipophilic moieties; and (2) synthetic approaches using size-defined nanomaterials, e.g., self-
assembling peptides, non-peptidic dendrimers, and gold nanoparticles, as antigen-displaying platforms. This review
summarizes the recent experimental studies directed to the development of multiple antigen-presenting peptide
vaccine systems.
Introduction
From the latter half of the 18
th century onwards, vacci-
nations have saved millions of human lives and count-
less animals, and vaccinology contributes to the
prevention of infectious diseases (e.g., polio, measles,
a n dr u b e l l a )a n da n t i s e r u m sf o rt o x o i d s( e.g., snake
bites, spider bites and jellyfish stings). However, there is
a strong demand for the development of safer and more
effective vaccines toward not only the prevention of
many infectious diseases, e.g., human immunodeficiency
virus (HIV) [1-3], malaria [4-6], group A streptococci
(GAS) [7,8], hepatitis C virus (HCV) [9,10], and severe
acute respiratory syndrome (SARS) [11,12], but also for
cancer immunotherapy [13-15]. Synthetic immunogenic
peptides are ideal vaccine subunit components because
of the following differences to traditional vaccines com-
posed of live-attenuated, killed or inactivated pathogens
e.g., bacteria or viruses: (1) no infectious material; (2) no
cross-reactivity with host tissues; (3) induction of site-
specific antibodies (Abs); (4) ability to chemically define
and modify products; and (5) swift large-scale manufac-
turing and long-term storage in the event of a
pandemic. However, the biological activity of peptides is
generally short due to enzymatic degradation, and small
peptides that are used as antigens are not recognized by
immune cells, e.g., dendritic cells (DCs) and macro-
phages, and do not elicit a strong immune response
when administered alone. The co-administration of
adjuvants (e.g., water-in-oil emulsions, oil-in-water
emulsions, liposomes, bacterial lipophilic compounds,
etc.) with subunit peptide antigens is one of the meth-
ods used to enhance the immune response; however,
only a few adjuvants are approved for clinical use [16].
Alternatively, short antigenic peptides induce strong
immune responses when co-administrated or engaged
with carrier proteins (e.g., ovalbumin (OVA), bovine
serum albumin, keyhole limpet hemocyanin, tetanus
toxoid, etc.); however, they are also associated with
undesirable effects such as the suppression of the anti-
peptide Ab response and the production of Abs against
the carrier proteins [17-22].
Tam developed the multiple antigenic peptide (MAP)
system to improve the poor immunogenicity of subunit
peptide vaccines [23]. In this MAP system, multiple
copies of antigenic peptides are simultaneously bound
to the a-a n dε-amino groups of a non-immunogenic
Lys-based dendritic scaffold (Figure 1). The protein-
sized MAP molecules acquire stability from enzymatic
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© 2011 Fujita et aldegradation, enhanced molecular recognition by
immune cells, and induction of stronger immune
responses compared with small antigenic peptides. The
MAP concept represented a major breakthrough for
vaccine systems and further improvements in a large
variety of multiple antigens-presenting peptide vaccine
systems have been investigated. This review focuses on
the current status of multiple antigen-presenting vaccine
approaches, especially the addition of functional compo-
nents and the application of a wide variety of synthetic
methods and size-defined nanomaterials, e.g., self-assem-
bling peptides, dendrimers and gold nanoparticles, as
antigen-displaying platforms.
Functional components
Tam’s MAP vaccines that carried several copies of pep-
tide antigens on a Lys-based dendrimer induced higher
Ab production than single peptide monomers and car-
rier protein-peptide conjugates; however, additional
components, such as an adjuvant, were required in
many cases. Therefore, great efforts have been directed
toward improvement of these MAP vaccines by the
incorporation of various functions into a single vaccine
molecule using helper T-cell epitopes, immune-stimu-
lant lipid moieties, or cell-penetrating peptides have
been conducted.
(1) Helper T-cell epitope
Antigens are taken up by antigen-presenting cells
(APCs) and B-cells and undergo proteolysis to form
peptide epitopes. Of them, T-cell epitopes are presented
by class II molecules of the major histocompatibility
complex (MHC) on the surface of APCs and B-cells.
APCs activate helper T-cells by the interaction between
the T-cell receptors on T-cells and the epitopes/MHC
class II complexes on the surface of APCs. The activated
helper T-cells recognize B-cells that have the same epi-
topes/MHC II complexes on their surfaces. This T-cell/
B-cell interaction is the trigger for the differentiation of
B-cells into plasma cells that secrete Abs. The use of
certain T-cell epitopes induces strong immune
responses, and carrier proteins are used as a source of
helper T-cell epitopes. Subunit peptide vaccines
containing only B-cell epitopes cannot always elicit
strong immune responses due to a lack of T-cell
activation.
The incorporation of helper T-cell epitopes into MAP
vaccines has been investigated [22,24]. MAP vaccines
containing B- and T-cell epitopes in a single construct
induced strong immune responses and have been stu-
died in clinical trials [25]. Although single vaccine mole-
cules containing B- and T-cell epitopes induced the
production of Abs against the defined T-cell epitopes, in
some cases, the Ab titers of the anti-T-cell epitopes
were mostly lower than those of B-cell epitopes [26,27].
(2) Lipophilic modifications
A wide variety of cells including B-cells, T-cells, DCs,
and macrophages express Toll-like receptors (TLRs) on
their surfaces. Eleven TLRs (named simply TLR-1 to
TLR-11) in human have been identified to date [28].
TLRs are a family of pattern-recognition receptors that
recognize structural components of many bacteria,
viruses and fungi, and play a critical role in the early
innate immune response. TLR-mediated stimulation of
APCs significantly enhances the secretion of pro-inflam-
matory cytokines, Ab production, and immune
responses and, TLR agonists may be able to be used in
alternative adjuvant systems.
Bacterial lipid components such as Pam3Cys (the
inner and outer membrane components of gram-nega-
tive bacteria) [29,30], and Pam2Cys (the lipid compo-
nent of macrophage-activating lipopeptide 2 isolated
from mycoplasma) [31,32] as well as synthetic a-lipo
amino acids [33,34] are characterized as TLR-2 agonists
and used as immune-stimulating lipophilic moieties
(Figure 2) that are attached to antigenic peptides (lipo-
peptides). Other lipophilic compounds such as O-acyl
serine, N-acyl lysine and glycolipids are also utilized for
this purpose [35-37]. Lipopeptides stimulate innate
immunity by their interaction with TLRs on DCs,
[38-42] and elicit long-lasting systemic immune
responses and T-cell proliferations [43-45], resulting in
the enhanced immunogenicity of unmodified peptides
by more than a few orders of magnitude. In addition,
lipopeptides show none of the harmful side effects of
adjuvants. Lipopeptide vaccines are currently in pre-clin-
ical and clinical trials treating HIV and hepatitis B virus
[46-48]. The incorporation of lipids with known
immune-stimulating characteristics into the MAP sys-
tem produces self-adjuvanting lipopeptide vaccine candi-
dates that can induce Ab and cellular responses in the
absence of additional adjuvants [33,49-52].
(3) Cell-penetrating peptides
Since the discovery of the cellular membrane translocat-
ing property of the human immunodeficiency virus
transactivating regulatory protein (HIV TAT), several
peptides with the ability to translocate to the plasma
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Figure 1 Lys-based MAP vaccines.
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trating peptides (CPPs). CPPs have been studied for
their ability to deliver peptides/proteins [53,54], oligonu-
cleotides/DNA/RNA [55-58], and even much bigger
molecules such as liposomes [59,60] into the cytoplasm
of cells. Fully exploiting this ability, CPPs are being uti-
lized in vaccine studies for the delivery of antigens to
APCs with the aim of antigen presentation and the
induction of an immune response [61,62]. CPP-antigen
conjugates enhance the cross-penetration of antigens
into DCs [63,64]; however, CPPs function in all cell
types, and a dual functionalized compound (CPP conju-
gation and DC targeting) that was designed in one study
showed no synergistic enhancement of the immune
response [65].
As such, numerous attempts to incorporate various
functional components into single molecules have been
performed. One consideration for the design of multiple
antigen-presenting vaccines composed of various com-
ponents is their molecular geometry, i.e., altering the
linkage and spatial arrangement of each component evi-
dently influences the conformational structure (lack of
a-helicity), solubility, and molecular recognition by
immune cells [27,66-71]. Zeng et al. studied the influ-
ence of diverse chemical linkages and epitope orienta-
tions on immunological activity [27]. Either N-terminus
or C-terminus of both T-cell epitope and B-cell epitope
were linked via disulfate, thioether, oxime, or peptide
bond. The immunological evaluation of the same epi-
tope-containing molecules with different linkages
showed unique properties in terms of their stabilities to
serum and the ability to induce Abs against T-cell and/
or B-cell epitopes. Abdel-Aal et al. studied the relation-
ship between immunological activity and the structural
arrangement of multiple antigens-presenting vaccine
molecules with 3 components (J14 as a B-cell epitope,
P25 as a CD4
+ T-cell epitope, and a-lipo amino acids),
showing clearly that changing the position of each com-
ponent significantly affected the production of IgG Abs
against B-cell epitopes and, in some cases, T-cell epi-
topes [66].
Structural platforms and enabling chemistry
In the case of the MAP systems, the number of peptide
epitopes that can be incorporated into a Lys-based den-
dritic scaffold is limited. Furthermore, stepwise solid
phase peptide synthesis (SPPS) of branching peptides
such as MAPs commonly encounters the difficulty of
purification to homogeneity and characterization of the
final products. Using purified short peptides as building
blocks, several chemoselective conjugation techniques (e.
g., native chemical ligation [52], thioether ligation
[72,73], thiazolidine/oxazolidine ligation [74], oxime
ligation [75], maleimide [76], and Cu(I)-catalyzed azide-
alkyne cycloaddition [77]) have been applied to the
synthesis of multiple antigen-presenting vaccines; how-
ever, the difficulties associated with the stoichiometrical
stepwise incorporation of many of the same or different
peptide epitopes into Lys-based dendritic scaffolds
remain [73,78-80]. Concerning the design, preparation
and biological activity of multiple antigen-presenting
vaccine molecules, the stoichiometric epitope density of
multivalent ligands is an important parameter [81,82].
Hence, we now introduce the alternative synthetic
approaches that are used to attach multiple copies of
antigenic peptides onto organic or inorganic scaffolds
instead of a Lys-based dendrimer.
(1) Radical-induced polymerization
Polymer chemistry using purified antigenic peptides is
suitable to prepare multiple antigen-presenting vaccine
molecules. Free radical-induced polymerization of vinyl
monomers is one of the most common and useful reac-
tions for making polymers. An acryloyl (CH2 = CHCO-)
group, as a key functional group for polymerization, can
easily be introduced into peptides during conventional
SPPS. Free radical-induced polymerization of acryloyl-
peptide building blocks yields polymeric immunogens
bearing hundreds of the same or different peptide
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Figure 2 Structure of immune-stimulating lipid moieties.
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[83-86]. The size of the polymer construct and the dis-
tance between individual peptidic components can be
controlled by the addition of acrylamide or its analog
along with chain transfer agents (dithiothreitol or mer-
captoacetic acid) during the polymerization process [85].
Jackson et al. evaluated the vaccine efficacy of poly-
meric immunogens containing 7 B-cell epitopes (88/30,
Y504S, BSA10, NS27, NS1, NS5, and PL1; the N-term-
inal GAS M protein sequences) and the chimeric pep-
tide J14 (a B-cell epitope consisting of the GAS M-
protein C-region and GCN4 DNA-binding protein
sequence). The polymeric GAS vaccine molecules
showed outstanding broad immunogenicity and protec-
tion from GAS infection in mice. Abs against each of
the individual epitopes presented in the polymers were
successfully elicited [86].
(2) Self-assembling nanoparticles as antigen-presenting
platforms
Peptides with certain helical or b-hairpin/sheet second-
ary structures can assemble themselves to form tubular,
fibrillar, or spherical structures on the nano-scale via
non-covalent interactions (e.g., van der Waals bonds,
electrostatic interactions, hydrogen bonds or stacking
interactions). They are called self-assembling peptides
and applied as topologically defined building blocks in
various fields including material sciences, molecular
electronics, tissue engineering, and drug delivery
[87-89]. The ability of these self-assembling peptides to
form nanostructures is also of great interest for a repeti-
tive antigen display system (Figure 4).
Burkhard’s group used self-assembling peptide nano-
particles composed of a pentameric coiled-coil oligomer-
ization domain derived from cartilage oligomeric matrix
protein [90] and a de novo trimeric coiled-coil oligomer-
ization domain [91] as multiple antigen-display
platforms [71,82]. An a-helical coiled-coil B-cell epitope
HRC1, derived from the SARS S protein, was then
attached on the self-assembling peptide nanoparticles.
Self-assembly in phosphate-buffered saline yielded nano-
particles (~ 25 nm in diameter) that exposed multiple
copies of HRC1 on their surface. Circular dichroism
(CD) spectra indicated that the peptide nanoparticles
maintain an a-helical conformation. Immunological eva-
luation of the nanoparticles containing HRC1 showed
specific Ab production and moderate neutralization
activity of SARS coronavirus infectivity [71]. Further-
more, immunization of mice with peptide nanoparticles
bearing the malaria B-cell epitope (DPPPPNPN)2Ds u c -
cessfully induced high Ab titers and long-lasting protec-
tion. The majority of these mice were protected against
an initial challenge of parasites for up to 6 months after
the last immunization or up to 15 months against a sec-
ond challenge [82]. This self-assembling peptide nano-
particle vaccine against Malaria is currently undergoing
pre-clinical trial in the US.
A short fibrillizing peptide Q11 self-assembles in a
salt-containing aqueous solution to form networks of b-
sheet-rich nanofibers with a width of 15 nm; and the
resulted nanoparticles are non-cytotoxic and minimally
immunogenic [92,93]. Rudra et al. used Q11 as a multi-
ple antigen-presenting vaccine system. Self-assembling
peptide nanofibers (O-Q11), in which the OVA323-339
epitope, derived from chicken egg OVA, and Q11 were
linked via a spacer, were subcutaneously administrated
into mice and elicited high IgG titers in the absence of
an additional adjuvant. The Ab titers were remarkably
higher compared with the admixture of OVA323-339 and
complete Freund’s adjuvant (CFA). According to this
study, Ab titers against Q11 were not determined even
when it was co-administrated with CFA [94].
The usage of a self-assembling non-peptidic dendritic
polymer as an antigen-display system was recently
reported. Multiple copies of J14 (B-cell epitope from the
GAS M-protein) were attached on dendrimers via Cu(I)-
catalyzed azide-alkyne cycloaddition and the subsequent
self-assembly was carried out in water to form nanopar-
ticles (20 nm in diameter). After subcutaneous immuni-
zation with the J14-bearing nanomolecules, several
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Figure 3 Vaccine molecules presenting a number of epitopes
on alkyl backbone formed by free radical-induced
polymerization of acryloyl groups.
Figure 4 Systematic self-assembling peptide vaccine with
repetitive antigens.
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any adjuvants [77].
(3) Gold nanoparticles as antigen carriers
As an alternative to organic compounds (certain pep-
tides or polymers), inorganic materials such as SiO2,
Ag, Pt, and Au are also known to form nanoparticles.
Colloidal gold nanoparticles (GNPs) are of interest for
various biomedical applications [95,96], e.g., imaging
[97-99], photo-activated therapeutics [100], tumor
detection [101], and drug delivery [102-104] as well
as multivalent antigen carrier scaffoldings [105-107]
instead of conventional carrier proteins and synthetic
dendrimers/polymers. GNPs are an ideal material pri-
marily because of their biocompatibility and lack of
immunogenicity [108,109]. GNPs can be easily pre-
pared from gold salt (H[AuCl4]) in water and their
particle sizes are controllable (ranging from 1-100 nm
in diameter) [110-113]; consequently, gold surface
electrodes can be readily reacted with molecules bear-
ing a mercapto (SH) group (Figure 5). The strong
attachment between the mercapto group and the gold
surface is easily prepared as well as the chemoselec-
tive conjugation, e.g., native chemical ligation, click
chemistry, oxime ligation, and thioether ligation
[52,72-77] of the antigenic peptide and synthetic core
particles (sophisticated in some cases). The size-
dependent toxicity of naked GNPs can be reduced by
modifying their surfaces [114]. The intracellular
uptake of GNPs is mediated through endocytosis
[115-117], enabling GNPs to deliver the attached
molecules into the cell. GNP-peptide conjugates resis-
tant to enzymatic and lysosomal degradation. As
such, GNPs are suitable materials to use as antigen-
presenting scaffolds.
Chen et al. demonstrated that the addition of extra
Cys residues to the C-terminus of an epitope, derived
from the VP1 protein of the foot-and-mouth disease
virus, allowed its conjugation to different sized GNPs as
antigen carriers. Mice that were immunized with these
GNP-epitope conjugates showed significant size-depen-
dent immunogenicity and biodistribution in the spleen
[107].
Conjugation with the Fc fragment from human IgG
targeting the Fcg receptor on human DCs into GNPs
successfully enhanced the cellular uptake of antigens. In
addition, GNP-epitope-Fc conjugates showed better
antigen-uptake activity, immunological responses and
lymphocyte proliferation compared with the use of lipo-
somes as an antigen-delivery system [118].
Conclusion
The current status of multiple antigens-presenting vac-
cine systems has been reviewed. Various functional
components (T-helper epitopes, immune-stimulating
lipids, and cell-penetrating peptides) have been attached
with antigens to improve subunit peptide vaccine poten-
tiation, such as the effective and selective activation of a
particular immune system and mucosal immunity.
Meanwhile, the recent use of size-defined organic and
inorganic nanomaterials without either immunogenicity
or cytotoxicity as antigen-display platforms surely
advances the development of subunit peptide vaccines
without the use of adjuvants. Each of these nanomater-
ials as antigen-display platforms, however, has short-
comings such as requirement of several synthetic steps
and cost. Optimization of the balance between vaccine
efficacy and the amounts or ratio of attached B-epitopes
and additional functional components, and exploring
alternative safe and economical materials for multiple
antigen-presenting systems instead of Au would help
reduce the cost for their practical use. As the optimiza-
tion of the balance continues to investigate, antigen-dis-
play platforms would be an ideal component to develop
vaccines.
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